{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:41:13Z","timestamp":1790775673965,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T00:00:00Z","timestamp":1631577600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jaadinternational.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD International"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.jdin.2021.09.002","type":"journal-article","created":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T05:02:45Z","timestamp":1634706165000},"page":"112-120","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Analysis of tumor response and clinical factors associated with vitiligo in patients receiving anti\u2013programmed cell death-1 therapies for melanoma: A\u00a0cross-sectional study"],"prefix":"10.1016","volume":"5","author":[{"given":"L\u00e9a","family":"Dousset","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alize","family":"Pacaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Barnetche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Kostine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Dutriaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Pham-Ledard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Beylot-Barry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"G\u00e9rard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sorilla","family":"Prey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Andreu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Boniface","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1139-0908","authenticated-orcid":false,"given":"Julien","family":"Seneschal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.jdin.2021.09.002_bib1","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","article-title":"Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial","volume":"19","author":"Hodi","year":"2018","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.jdin.2021.09.002_bib2","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study","volume":"20","author":"Robert","year":"2019","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.jdin.2021.09.002_bib3","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1158\/1078-0432.CCR-15-1136","article-title":"Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes","volume":"22","author":"Freeman-Keller","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.jdin.2021.09.002_bib4","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2014.57.4756","article-title":"Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis","volume":"33","author":"Teulings","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jdin.2021.09.002_bib5","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","article-title":"Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab","volume":"152","author":"Hua","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.jdin.2021.09.002_bib6","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/1346-8138.13520","article-title":"Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: a multi-institutional retrospective study","volume":"44","author":"Nakamura","year":"2017","journal-title":"J Dermatol"},{"issue":"5","key":"10.1016\/j.jdin.2021.09.002_bib7","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaad.2016.10.044","article-title":"Vitiligo-like lesions occurring in patients receiving anti-programmed cell death\u20131 therapies are clinically and biologically distinct from vitiligo","volume":"76","author":"Larsabal","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jdin.2021.09.002_bib8","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1093\/annonc\/mdp325","article-title":"Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: results from a single-institution hospital-based observational cohort study","volume":"21","author":"Quaglino","year":"2010","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.jdin.2021.09.002_bib9","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jaad.2015.10.029","article-title":"Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: a single-institution cohort","volume":"74","author":"Hwang","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jdin.2021.09.002_bib10","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.jdin.2021.09.002_bib11","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jdin.2021.09.002_bib12","first-page":"472","article-title":"Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.jdin.2021.09.002_bib13","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.jdin.2021.09.002_bib14","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.jaad.2019.11.017","article-title":"Vitiligo under anti\u2013programmed cell death-1 therapy is associated with increased survival in melanoma patients","volume":"82","author":"Nardin","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jdin.2021.09.002_bib15","doi-asserted-by":"crossref","first-page":"adv00001","DOI":"10.2340\/00015555-3319","article-title":"Clinical and pathological relevance of drug-induced vitiligo in patients treated for metastatic melanoma with anti-PD1 or BRAF\/MEK inhibitors","volume":"100","author":"Ramondetta","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jdin.2021.09.002_bib16","first-page":"283","article-title":"Immunotherapy \u201cshock\u201d with vitiligo due to nivolumab administration as third line therapy in lung adenocarcinoma","volume":"22","author":"Zarogoulidis","year":"2017","journal-title":"Respir Med Case Rep"},{"issue":"2","key":"10.1016\/j.jdin.2021.09.002_bib17","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jdcr.2016.10.008","article-title":"Nivolumab-associated vitiligo-like depigmentation in a patient with acute myeloid leukemia: a novel finding","volume":"3","author":"Yin","year":"2017","journal-title":"JAAD Case Rep"},{"issue":"4","key":"10.1016\/j.jdin.2021.09.002_bib18","doi-asserted-by":"crossref","first-page":"435","DOI":"10.23736\/S0392-0488.18.06254-5","article-title":"Vitiligo-like lesions occurring in patients receiving anti-programmed cell death-1 therapies","volume":"154","author":"Dousset","year":"2019","journal-title":"G Ital Dermatol Venereol"},{"issue":"581","key":"10.1016\/j.jdin.2021.09.002_bib19","doi-asserted-by":"crossref","first-page":"eabd8636","DOI":"10.1126\/scitranslmed.abd8636","article-title":"Epitope spreading toward wild-type melanocyte-lineage antigens rescues suboptimal immune checkpoint blockade responses","volume":"13","author":"Lo","year":"2021","journal-title":"Sci Transl Med"},{"issue":"10","key":"10.1016\/j.jdin.2021.09.002_bib20","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/nri.2016.90","article-title":"Sex differences in immune responses","volume":"16","author":"Klein","year":"2016","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"10.1016\/j.jdin.2021.09.002_bib21","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S1470-2045(18)30078-0","article-title":"Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis","volume":"19","author":"McQuade","year":"2018","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.jdin.2021.09.002_bib22","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S1470-2045(18)30261-4","article-title":"Cancer immunotherapy efficacy and patients\u2019 sex: a systematic review and meta-analysis","volume":"19","author":"Conforti","year":"2018","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.jdin.2021.09.002_bib23","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1001\/jamaoncol.2018.5904","article-title":"Association of patient sex with efficacy of immune checkpoint inhibitors and overall survival in advanced cancers: a systematic review and meta-analysis","volume":"5","author":"Wallis","year":"2019","journal-title":"JAMA Oncol"},{"issue":"8","key":"10.1016\/j.jdin.2021.09.002_bib24","doi-asserted-by":"crossref","first-page":"e2012534","DOI":"10.1001\/jamanetworkopen.2020.12534","article-title":"Association of sex, age, and Eastern Cooperative Oncology Group performance status with survival benefit of cancer immunotherapy in randomized clinical trials: a systematic review and meta-analysis","volume":"3","author":"Yang","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.jdin.2021.09.002_bib25","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1038\/s41467-020-15679-x","article-title":"Sex-associated molecular differences for cancer immunotherapy","volume":"11","author":"Ye","year":"2020","journal-title":"Nat Commun"},{"issue":"9","key":"10.1016\/j.jdin.2021.09.002_bib26","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1111\/jdv.16311","article-title":"Cutaneous adverse events: a predictor of tumour response under anti-PD-1 therapy for metastatic melanoma, a cohort analysis of 189 patients","volume":"34","author":"Bottlaender","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"10.1016\/j.jdin.2021.09.002_bib27","doi-asserted-by":"crossref","first-page":"e176","DOI":"10.1111\/jdv.14678","article-title":"Focal regression of a primary melanoma, fading lentigines and poliosis in metastatic melanoma treated with anti-PD-1","volume":"32","author":"Thomas","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jdin.2021.09.002_bib28","doi-asserted-by":"crossref","first-page":"100799","DOI":"10.1016\/j.ajoc.2020.100799","article-title":"Progressive choroidal thinning (leptochoroid) and fundus depigmentation associated with checkpoint inhibitors","volume":"19","author":"Canestraro","year":"2020","journal-title":"Am J Ophthalmol Case Rep"}],"container-title":["JAAD International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666328721000705?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666328721000705?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T20:59:59Z","timestamp":1762981199000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666328721000705"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":28,"alternative-id":["S2666328721000705"],"URL":"https:\/\/doi.org\/10.1016\/j.jdin.2021.09.002","relation":{},"ISSN":["2666-3287"],"issn-type":[{"value":"2666-3287","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analysis of tumor response and clinical factors associated with vitiligo in patients receiving anti\u2013programmed cell death-1 therapies for melanoma: A\u00a0cross-sectional study","name":"articletitle","label":"Article Title"},{"value":"JAAD International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdin.2021.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Inc on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}